These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23676856)

  • 1. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children.
    Yoshizawa K; Ikawa K; Ikeda K; Ohge H; Morikawa N
    Pediatr Infect Dis J; 2013 Nov; 32(11):1208-16. PubMed ID: 23676856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data.
    Yoshizawa K; Ikawa K; Ikeda K; Kumon H; Ohge H; Morikawa N
    Int J Antimicrob Agents; 2012 Nov; 40(5):427-33. PubMed ID: 22877766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0.5-h and 3-h infusions.
    Lipš M; Siller M; Strojil J; Urbánek K; Balík M; Suchánková H
    Int J Antimicrob Agents; 2014 Oct; 44(4):358-62. PubMed ID: 25216543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and pharmacokinetic study of imipenem/cilastatin in children and newborn infants].
    Bégué P; Quinet B; Baron S; Challier P; Fontaine JL; Lasfargues G
    Pathol Biol (Paris); 1989 May; 37(5):485-90. PubMed ID: 2674874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.
    Jaruratanasirikul S; Vattanavanit V; Wongpoowarak W; Nawakitrangsan M; Samaeng M
    Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):735-747. PubMed ID: 32886347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.
    Couffignal C; Pajot O; Laouénan C; Burdet C; Foucrier A; Wolff M; Armand-Lefevre L; Mentré F; Massias L
    Br J Clin Pharmacol; 2014 Nov; 78(5):1022-34. PubMed ID: 24903189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic-pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Ohge H; Sueda T; Taniwaki M
    J Infect Chemother; 2008 Apr; 14(2):130-6. PubMed ID: 18622676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates.
    Bégué PC; Baron S; Challier P; Fontaine JL; Lasfargues G
    Scand J Infect Dis Suppl; 1987; 52():40-5. PubMed ID: 3483288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
    Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
    J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Dosing Optimization of Imipenem in Children with Hematological Malignancies.
    Dong L; Zhai XY; Yang YL; Wang L; Zhou Y; Shi HY; Tang BH; Wu YE; Yang F; Wen L; Kong HX; Zhi LJ; Jacqz-Aigrain E; Zhao W
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and Pharmacodynamic Analysis of Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Imipenem.
    Li Z; Bai J; Wen A; Shen S; Duan M; Li X
    Clin Ther; 2020 Aug; 42(8):1564-1577.e8. PubMed ID: 32741646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS; Kinzig-Schippers M; Nafziger AN; Ma L; Sörgel F; Jones RN; Drusano GL; Bertino JS
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):251-8. PubMed ID: 20851549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis.
    Nomura K; Morikawa N; Ikawa K; Ikeda K; Fujimoto Y; Shimizu D; Taniguchi K; Shimura K; Kanbayashi Y; Komori T; Matsumoto Y; Fujita N; Shimazaki C; Taniwaki M
    J Antimicrob Chemother; 2008 Apr; 61(4):892-900. PubMed ID: 18276604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.